Authors: Zilberman-Itskovich S, Catalogna M, Sasson E, Hadanny A, Lang E, Finci S et al. PMID: 36261911 DOI: 10.1097/01.NAJ.0000897152.36663.7a Abstract According to this study: Hyperbaric oxygen therapy can improve cognitive function, psychiatric symptoms, pain, and fatigue in patients who have post-COVID-19 condition.The beneficial effect of the therapy can be attributed to increased brain perfusion and [...]

Authors: Bek LM, Berentschot JC, Huijts S, Vlake JH, Aerts JG PMID: 36284829 PMCID: PMC9421428 DOI: 10.1183/23120541.00355-2022 Abstract Introduction: A large proportion of patients experience a wide range of sequelae after acute COVID-19, especially after severe illness. The long-term health sequelae need to be assessed. Our objective was to longitudinally assess [...]

Authors: Arbel R, Sagy YW, Hoshen M, Battat E, Lavie G, Sergienko R et al. PMID: 36001529 PMCID: PMC9454652 DOI: 10.1056/NEJMoa2204919 Abstract Background: The oral protease inhibitor nirmatrelvir has shown substantial efficacy in high-risk, unvaccinated patients infected with the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data regarding the effectiveness of [...]

Authors: Carpene G, Negrini D, Henry BM, Montagnana L, Lippi G PMID: 35704707 DOI: 10.1515/dx-2022-0042 Abstract Objectives: Coronavirus disease 2019 (COVID-19) is a life-threatening infectious disorder characterized by a sustained prothrombotic state. Since homocysteine is a potential biomarker of thrombotic diseases, the aim of this article is to provide an updated overview on the possible [...]

Authors: Charnley M, Islam S, Bindra G, Ratcliffe J, Zhou J, Hulett M Abstract COVID-19 is primarily known as a respiratory disease caused by SARS-CoV-2. However, neurological symptoms such as memory loss, sensory confusion, severe headaches, and even stroke are reported in up to 30% of cases and can persist even after the infection is [...]

Authors: Mostafa-Hedeab G, Al-kuraishy HM, Al-Gareeb AA, Jeandet P, Saaad HM, El-Saber Batiha G PMID: 35486310 PMCID: PMC9051499 DOI: 10.1007/s10787-022-00993-1 Abstract The existing pandemic viral infection caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as an entry-point into affected cells and [...]

Authors: Gupta K, Strymish J, Stack G, Chamess M DOI: https://doi.org/10.21203/rs.3.rs-1588371/v1 Abstract Initiation of NM/R treatment on Day 0 in a 71-year-old vaccinated and boosted male resulted in rapid resolution of COVID-19 symptoms followed one week later by the development of typical cold symptoms. SARS-CoV-2 viral load fluctuated in parallel with symptoms, with two distinct [...]

Authors: Brown JT, Saigal A, Karia N, Patel RK, Razvi Y, Steeden JA PMID: 35470679 PMCID: PMC9238618 DOI: 10.1161/JAHA.121.024207 Abstract Background Ongoing exercise intolerance of unclear cause following COVID-19 infection is well recognized but poorly understood. We investigated exercise capacity in patients previously hospitalized with COVID-19 with and without self-reported exercise [...]

Authors: Burakgazi AZ PMID: 35702058 PMCID: PMC9149535 doi: 10.1159/000524205 Abstract COVID-19 has caused several neurological complications by affecting the central and peripheral nervous systems (PNS). Studies on the PNS involvement in COVID-19 are limited. These complications are likely unreported, given the difficulty of obtaining further diagnostic information, such as expert neurologist evaluation, electrodiagnostic testing, and [...]

Authors: Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W DOI: 10.1056/NEJMoa2118542 Abstract BACKGROUND Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus activity in vitro. METHODS We conducted a phase 2–3 double-blind, randomized, controlled trial in which symptomatic, [...]